Therefore, even if only shown in one highly specific and resistant clinical case, these data provide significant translational value supporting the performance of future studies to verify the treatment of resistant patients with RAS/RAF/MAPK and/or STAT5 hyperactivation, which are cases that are difficult to cure and show low overall survival in myeloid leukemias [10, 64]. This evidence concerns the gene RAF1 and myeloid leukemia.